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Background. Intravenous iron allows for efficient and well-tolerated treatment in iron deficiency and is routinely used in diseases of
the gastrointestinal tract. Objective. The aims of this study were to determine the probability of relapse of iron deficiency over time
and to investigate treatment routine, effectiveness, and safety of iron isomaltoside.Methods. A total of 282 patients treated with iron
isomaltoside were observed for two treatments or a minimum of one year. Results. Out of 282 patients, 82 had Crohn’s disease and
67 had ulcerative colitis. Another 133 patients had chronic blood loss, malabsorption, or malignancy. Patients who received an iron
isomaltoside dose above 1000mg had a 65% lower probability of needing retreatment compared with those given 1000mg. A
clinically significant treatment response was shown, but in 71/191 (37%) of patients, anaemia was not corrected. The mean
dose given was 1100mg, lower than the calculated total iron need of 1481mg. Adverse drug reactions were reported in 4% of
patients. Conclusion. Iron isomaltoside is effective with a good safety profile, and high doses reduce the need for retreatment
over time. Several patients were anaemic after treatment, indicating that doses were inadequate for full iron correction. This trial
is registered with NCT01900197.
1. Introduction
Intravenous (IV) iron allows for efficient and well-tolerated
treatment in iron deficiency and is routinely used in diseases
of the gastrointestinal tract. In inflammatory bowel disease
(IBD), iron deficiency anaemia is the most common systemic
complication and has been reported in 20–42% of patients
[1–7], while iron deficiency has been reported in 35–90% of
patients [1, 2, 6, 8–10]. Anaemia has been shown to nega-
tively affect health-related quality of life and contribute to
chronic fatigue in IBD patients [9, 11, 12].
According to current guidelines, iron supplementation
should be administered in all cases of IBD with iron defi-
ciency anaemia and to prevent recurrence of anaemia after
prior iron supplementation [13]. In iron deficiency with-
out anaemia, an individualised approach is recommended
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[13, 14]. The use of oral iron supplementation has limita-
tions in clinical practice, including reduced efficiency, poor
tolerance, and low adherence, and thus, IV iron is widely
recommended [13, 15–17]. IBD patients with iron deficiency
usually need high doses of iron, and full iron correction is
in such cases only possible with IV iron treatment [13, 18].
Iron deficiency often recurs in IBD patients after iron
replacement therapy [13, 18–20]. Additionally, many IBD
patients do not receive adequate treatment for iron defi-
ciency, and increased awareness and optimised treatment
strategies are needed [3, 6, 21].
Iron isomaltoside 10% (Monofer®, Pharmacosmos A/S,
Denmark) is a high-dose IV iron for fast infusion. The
strongly bound formulation of iron and the carbohydrate
isomaltoside in a matrix structure enables a controlled
slow release of iron with small risk of iron toxicity. This
allows for administration of high doses of iron in one visit.
More than 3000 patients have been treated with iron isomal-
toside in clinical studies until now, and more than 5.3
million doses have been used in clinical practice (data on file,
Pharmacosmos A/S, Denmark).
The aims of this study were to determine the probability
of relapse of iron deficiency over time, defined as retreatment
related to the dose given, and further to investigate treatment
routine, effectiveness, and safety of iron isomaltoside in
clinical practice.
2. Materials and Methods
2.1. Study Design and Population. Participants were recruited
from a total of 10 sites in Denmark, Norway, and Sweden in a
prospective, observational study conducted from August
2013 to November 2015. Inclusion criteria were age> 17
years and diagnosed with iron deficiency anaemia following
local clinical guidelines. The patients were treated with iron
isomaltoside according to the product label and clinical
routine. The patients were followed prospectively for two
treatments of iron isomaltoside given or for a minimum of
12 months after the first treatment. For patients not receiving
two treatments, the observation time lasted until completion
of the study in order to capture a second treatment. Due to
the observational design of the study, all procedures were
done according to local clinical practice and decisions by
the participating investigators.
2.2. Data Collection. Data for iron isomaltoside treatment
were collected prospectively for up to two treatments per
patient. The dose administered in the study and the calcu-
lated iron need [13, 22] were recorded. Use of concomitant
medication and pre- and posttreatment blood tests was also
recorded. Data were collected from medical records. Treat-
ment response was defined as normalisation of haemoglobin
(Hb) or increase in Hb≥ 2 g/dL [23, 24]. The occurrence of
adverse drug reactions (ADRs) was registered and reported
to the sponsor’s pharmacovigilance department and accord-
ing to national reporting systems. The collected data were
systematically entered into an electronic case report form
(eClinicalOS, Merge Healthcare, NC, USA; licensed by
BioStata ApS, Denmark).
2.3. Statistical Methods. The safety analysis set population
(n = 282) included all patients who were enrolled in the
study and received the study drug, and the effectiveness
analysis set population (n = 278) included all patients
who received a full prescribed dose. The patient flow
diagram is shown in Figure 1.
Data are presented with mean and standard deviation or
median and range, for continuous variables, and with a
number of exposed subjects with percentages for categorical
variables. The probability of iron isomaltoside retreatment
over time was analysed using a Cox proportional hazards
model and was determined from survival plots. Laboratory
parameter changes were obtained from an analysis of covari-
ance model. The effect of the iron dose on the Hb response
was analysed by logistic regression. The significance cut-off
for all analyses was p < 0 05. No formal adjustment for
multiplicity was performed. Data were analysed using SAS
version 9.4 (SAS Institute, USA).
2.4. Ethical Considerations. The Regional Ethics Committee
in Sweden (EPN Lund 2013/231), the Data Protection Official
for Research in Norway (2013/10419), and the Danish Data
Protection Agency (2013–41-1543) approved the study. The
study was registered at ClinicalTrials.gov (NCT01900197).
All study participants gave written, informed consent before
inclusion, and the study was performed in accordance with
the Declaration of Helsinki and the European Medicines
Agency criteria for noninterventional studies [25].
3. Results
3.1. Patients. A total of 282 patients were included in the
study, and of these, 82 (29%) had Crohn’s disease (CD) and
67 (24%) had ulcerative colitis (UC). A remaining group of
133 (47%) non-IBD patients was iron deficient due to
chronic blood loss, malabsorption, or malignancy. At
baseline, the use of concomitant medications for anaemia
correction was low (oral iron 13%, blood transfusion 3%,
erythropoiesis-stimulating agents 0.4%, and cobalamin or
folic acid 28%). Baseline characteristics of the study popula-
tion are summarised in Table 1. As shown, most patients
having available ferritin data at baseline (both IBD and
non-IBD patients) were iron deficient with a ferritin cut-
off< 100 μg/L for iron deficiency. Not enough data for CRP
were collected to be able to assess inflammation status.
3.2. Probability of Retreatment and Treatment Routine. Of
the 278 patients receiving a full prescribed dose of iron
isomaltoside, 53 (19%) were given >1000mg, 186 (67%) were
given 1000mg, and 39 (14%) were given <1000mg at the first
treatment. In 264/278 (95%) of patients, the full prescribed
dose was administered in one single visit for the first iron
isomaltoside treatment.
The majority of patients, 170/278 (61%), received only
one treatment of iron isomaltoside during a median observa-
tion time of 19 (1–27) months. In 108/278 (39%) of patients
who were retreated, those who received a dose> 1000mg at
the first treatment had a 65% lower probability (hazard ratio:
0.351; 95% confidence interval (CI): 0.19, 0.66) of needing
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retreatment compared to those given 1000mg. For patients
who received a dose< 1000mg at the first treatment, there
was 36% higher probability (hazard ratio: 1.358; 95% CI:
0.81, 2.27) of needing retreatment compared to patients
given 1000mg. The hazard ratios were corrected for dose,
diagnosis, and baseline Hb. The probability of retreatment
at 52 weeks split by dose is shown in Figure 2.
In addition to the administered dose, baseline Hb was an
independent predictor of the probability for retreatment,
where the need for retreatment decreased by 18% (hazard
ratio: 0.825; 95% CI: 0.74, 0.90) for each 1 g/dL unit higher
baseline Hb. When comparing patients with CD and UC to
non-IBD patients, there were no significant differences in
the need for retreatment.
3.3. Effectiveness. Effectiveness was assessed around 7 weeks
after the first iron isomaltoside treatment (see Table 2 and
Figure 3). Treatment response following the first treatment
was achieved in 143/191 (75%) of the patients who were
anaemic at baseline. The response rate after the first treat-
ment increased significantly with an increasing iron isomal-
toside dose (8/14 [57%] for doses< 1000mg, 93/128 [73%]
for doses of 1000mg, and 42/49 [86%] for doses> 1000mg)
even when correcting for baseline Hb (p < 0 05). Of patients
with anaemia at baseline, 71/191 (37%) were still anaemic
following the first treatment.
3.4. Dosing in Clinical Practice and Calculated Iron Need. The
calculated iron need using the Ganzoni formula and simpli-
fied dosing compared to the actual dose given in the study
are shown in Table 3.
3.5. Safety. Twelve ADRs were reported in 10/282 (4%) of the
patients given a total of 408 high-dose iron isomaltoside
administrations. ADRs were seen in seven IBD patients and
three non-IBD patients. Infusion reactions were reported in
6/282 (2%) of patients; the rest were delayed hypersensitivity
reactions. One of the patients was admitted to the hospital for
the treatment of a serious acute infusion reaction with
generalised erythema, dyspnoea, general body pain mainly
localised to the abdomen, and hypotension. We found no
association between dose given and ADRs reported. All
patients had uneventful recoveries.
4. Discussion
The main result of this study was that the probability of
retreatment with IV iron could be reduced with dosing above
1000mg. Most patients were given doses of 1000mg or
higher, and the majority received their full prescribed dose
in one single visit and were treated only once during the
observation period. The administered dose of iron isomalto-
side and baseline Hb were independent predictors for
Eligible ( n = 282)
(i) IBD CD (
(ii) IBD UC (
(iii) Non-IBD (
Safety analysis set (n = 282)
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Reasons: >1 treatment (n = 109) or 1
Not completed (n = 13)
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(ii) IBD UC (n = 4)
(iii) Non-IBD (n = 5)
Reason: 1 treatment and <1 year follow-up
Effectiveness analysis set (n = 278)
(i) IBD CD (n = 80)
(ii) IBD UC (n = 66)
(iii) Non-IBD (n = 132)
Excluded from analysis (did not receive
Analysis
Follow-up
Enrolment
treatment with ≥1 year follow-up (n = 160)
full prescribed dose, n = 4)
n = 82)
n = 67)
n = 133)
Figure 1: Patient flow diagram (based on CONSORT 2010). CD: Crohn’s disease; IBD: inflammatory bowel disease; UC: ulcerative colitis.
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Table 1: Demographic and baseline characteristics.
IBD CD
(n = 82)
IBD UC
(n = 67)
Non-IBD
(n = 133)
Total
(n = 282)
n (%)
Gender
Female 46 (56.1) 34 (50.7) 93 (69.9) 173 (61.3)
Male 36 (43.9) 33 (49.3) 40 (30.1) 109 (38.7)
Anaemica patients (n = 82) (n = 67) (n = 132) (n = 281)
56b (68.3) 44b (65.7) 98 (74.2) 198 (70.5)
Patients with Hb< 10 g/dL (n = 82) (n = 67) (n = 132) (n = 281)
14 (17.1) 11 (16.4) 41 (31.1) 66 (23.5)
Mean (SD)
Age, years (n = 82) (n = 67) (n = 133) (n = 282)
42.2 (16.2) 41.1 (15.9) 54.3 (18.6) 47.6 (18.4)
Weight, kg (n = 78) (n = 64) (n = 132) (n = 274)
73.1 (17.3) 76.4 (15.4) 74.6 (16.4) 74.6 (16.4)
Hb, g/dL (n = 82) (n = 67) (n = 132) (n = 281)
11.6 (1.7) 11.5 (1.7) 10.9 (1.9) 11.3 (1.8)
TSAT, % (n = 55) (n = 41) (n = 59) (n = 155)
9.9 (7.1) 9.4 (6.5) 10.3 (7.3) 9.9 (7.0)
Ferritin, μg/L (n = 70) (n = 63) (n = 117) (n = 250)
34.3 (59.8) 28.3 (59.1) 23.9 (84.9) 27.9 (72.4)
Median (IQR)c 11.0 (6.2–27) 11.0 (7.0–21) 9.0 (5.6–16) 10.0 (6.0–20)
aHb < 13 g/dL (men) and Hb < 12 g/dL (women). bMean (SD) Hb in IBD patients 10.8 (1.4) g/dL and mean (SD) weight 75.4 (17.4) kg. cMedian is presented for
data not normally distributed. CD: Crohn’s disease; Hb: haemoglobin; IBD: inflammatory bowel disease; IQR: interquartile range; SD: standard deviation;
TSAT: transferrin saturation; UC: ulcerative colitis.
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Figure 2: Probability of retreatment related to iron isomaltoside dose. The survival plot was obtained by using the Cox proportional hazards
model with dose and diagnosis as factors and baseline haemoglobin as covariate. The probability (percent) of retreatment with iron
isomaltoside at 52 weeks after the first treatment for each dose group was calculated from the survival curve. The number of patients at
weeks 0, 52, and 100 for each dose group includes all patients.
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retreatment. The response rate increased with higher dose;
however, several patients remained anaemic after treatment
indicating that patients receive inadequate iron dosing in
routine clinical practice.
To our knowledge, no other studies have shown that
higher doses of IV iron reduce the need for retreatment
over time. In a Swedish observational study, it was dem-
onstrated that the effect of IV iron treatment in IBD
patients was mostly sustained for a year with up to 29%
of patients being retreated within this period. In this
study, however, association to an administered dose was
not evaluated [26]. In an Austrian retrospective study
Table 2: Change in iron and blood cell parameters after the first iron isomaltoside treatment.
Pretreatment Posttreatment Concentration change p valuea Time of evaluationb
Mean (SD)
Hb, g/dL
(n = 191)c 10.5 (1.5) 12.5 (1.4) 2.0 (1.4) <0.0001 7.1 (6.0)
TSAT, %
(n = 108)d 9.6 (6.5) 21.0 (9.8) 11.4 (10.0) <0.0001 7.6 (5.0)
Ferritin, μg/L 25.0 (68.0) 146.3 (173.1) 121.3 (162.6) <0.0001 7.4 (6.5)
Median (IQR)e
(n = 222)d 10.0 (6.0–20) 95.0 (49–181) 71.0 (35–157)
ap values for concentration changes obtained by analysis of covariance test with diagnosis and dose as factors and pretreatment laboratory parameter
concentration as covariate. bTime (weeks) between the last administration of first iron isomaltoside treatment and blood test follow-up. cAnaemic patients
(Hb < 13 g/dL for men and Hb < 12 g/dL for women at baseline) with available pre- and posttreatment Hb measures in the total population. dPatients with
available pre- and posttreatment laboratory measures in the total population. eMedian is presented for data not normally distributed. Hb: haemoglobin;
IQR: interquartile range; SD: standard deviation; TSAT: transferrin saturation.
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Figure 3: Change in haemoglobin (Hb) after the first iron isomaltoside treatment in anaemic patients with available pre- and posttreatment
Hb measures. The time of evaluation corresponded to the time between the last administration of first iron isomaltoside treatment and blood
test follow-up and occurred during a mean (SD) time of 7.1 (6.0) weeks for anaemic patients at baseline and during a mean (SD) time of 6.1
(4.7) weeks for patients with Hb< 10 g/dL at baseline. The p value calculations were obtained by analysis of covariance test with diagnosis and
dose as factors and pretreatment laboratory parameter concentration as covariate.
Table 3: Study dose versus calculated iron need for anaemic patients.
Anaemic patientsa
IBD CD
(n = 50)
IBD UC
(n = 40)
Non-IBD
(n = 95)
Total
(n = 185)
Mean (SD)
Study doseb, mg 1058 (338.1) 1115 (265.6) 1115 (305.6) 1100 (306.2)
Iron need calculated from simplified dosing table, mg 1420 (325.1) 1438 (324.0) 1532 (316.3) 1481 (322.9)
Iron need calculated from Ganzoni formulac, mg 1268 (279.4) 1261 (316.0) 1380 (284.1) 1324 (294.2)
aAnaemia defined as Hb < 13 g/dL for men andHb < 12 g/dL for women at baseline. Patients having a weight < 50 kg and patients with missing weight data were
excluded. bStudy dose for first iron isomaltoside treatment. cGanzoni formula based on a target Hb of 15 g/dL, Hb level before first iron isomaltoside treatment
in study, and iron store of 500mg. CD: Crohn’s disease; Hb: haemoglobin; IBD: inflammatory bowel disease; SD: standard deviation; UC: ulcerative colitis.
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following IBD patients treated with iron sucrose, the dose
given had no influence on the need for retreatment over
time [19].
In line with other studies, we found that the response rate
correlated to the iron dose given [19, 20, 27]. There are few
observational studies of IV iron in clinical practice in IBD
[26, 28–30]. None of these have evaluated the dose given
compared to the dose needed for full iron correction. In our
study, we found that lower doses than the calculated iron
need as recommended by international guidelines were given
in clinical practice [13].
Treatment with IV iron in the current study showed a
good safety profile with a frequency of hypersensitivity
reactions similar to that reported in other studies even if
high doses were given to the majority of our patients
[15, 18–20, 26–29, 31, 32].
The limitation of our study is the observational design,
but one of the aims of the study was to observe treatment
routines in clinical practice to provide guidance for opti-
mised treatment strategies for IV iron treatment. Hence, no
instructions were given on dosing, time to effectiveness
assessment, and retreatment. We did not collect data on clin-
ical disease activity or anti-inflammatory treatment, which
can influence recurrence of anaemia and the need for iron
retreatment in patients with IBD.
Taken together, iron isomaltoside was effective with a
good safety profile in both IBD and non-IBD patients with
iron deficiency. A high dose, especially over 1000mg,
reduced the need for retreatment. The administration of
higher doses, as recommended in current guidelines, seems
required for the full iron correction and prevention of iron
deficiency anaemia.
5. Conclusions
In this study, we show that iron isomaltoside allows for
efficient and well-tolerated treatment in iron deficiency
and furthermore that high doses reduce the need for
retreatment over time. Several patients were anaemic after
treatment, indicating that doses routinely given were inad-
equate for full iron correction. Infusion reactions were
reported in 2% of patients, similar to what has been
reported in clinical trials.
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